Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program

Breast Cancer Research and Treatment

Volumn 139, Issue 1, 2013, Pages 155-161

  Møller, Pål ^a   Stormorken, Astrid ^a   Jonsrud, Christoffer ^b   Holmen, Marit Muri ^c   Hagen, Anne Irene ^d,e   Clark, Neal ^a   Vabø, Anita ^a   Sun, Ping ^f   Narod, Steven A ^f   Mæhle, Lovise ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

BRCA1; Breast cancer; Mammography; MRI; Screening; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENE MUTATION; HEALTH PROGRAM; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MUTATIONAL ANALYSIS; NORWAY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EARLY DETECTION OF CANCER; FEMALE; GENES, BRCA1; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; MUTATION; NORWAY;

EID: 84877583359     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2540-z     Document Type: Article

References (15)

1. Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692-695
2. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130
3. Møller P, Maehle L, Vabø A et al (2013) Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. Clin Genet 83:88-91
4. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017-2022
5. Warner E, Hill K, Causer P et al (2011) Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29:1664-1669
6. Rijnsburger AJ, Obdeijn IM, Kaas R et al (2010) BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 28:5265-5273
7. Passaperuma K, Warner E, Causer PA et al (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 107:24-30
8. Leach MO, Boggis CR, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365:1769-1778
9. Norwegian Breast Cancer Group: NBCGs treatment recommendations. http://www.nbcg.no/nbcg.blaaboka.html. Accessed 15 April 2013
10. Norwegian Directorate for Health, IS-1524: National action plan with guidelines for diagnosis, treatment and follow-up of patients with breast cancer. http://www.helsedirektoratet.no/publikasjoner/nasjonalt- handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av- pasienter-med-brystkreft/Sider/default.aspx. Accessed 15 April 2013
11. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434
12. Narod SA, Metcalfe K, Lynch HT et al (2013) Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat 138(1):273-279. doi: 10.1007/s10549-013-2429-x
13. Foulkes WD, Metcalfe K, Hanna W et al (2003) Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98:1569-1577
14. Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379
15. Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244